BACKGROUND: This phase Ib study aimed to establish the feasible everolimus dose given with standard-dose etoposide plus cisplatin (EP) for extensive-stage small-cell lung cancer (SCLC). PATIENTS AND METHODS: An adaptive Bayesian dose-escalation model and investigator opinion were used to identify feasible daily or weekly everolimus doses given with EP in adults with treatment-naive extensive-stage SCLC. A protocol amendment mandated prophylactic granulocyte colony-stimulating factor (G-CSF). Primary end point was cycle 1 dose-limiting toxicity (DLT) rate. Secondary end points included safety, relative EP dose intensity, pharmacokinetics, and tumor response. RESULTS: Patients received everolimus 2.5 or 5 mg/day without G-CSF (n=10; cohort A), 20 or 30 mg/week without G-CSF (n=18; cohort B), or 2.5 or 5 mg/day with G-CSF (n=12; cohort C); all received EP. Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively. Cycle 1 DLTs were neutropenia (cohorts A and B), febrile neutropenia (all cohorts), and thrombocytopenia (cohorts A and C). The most common grade 3/4 adverse events were hematologic. Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively). CONCLUSIONS: Everolimus 2.5 mg/day plus G-CSF was the only feasible dose given with standard-dose EP in untreated extensive-stage SCLC.
BACKGROUND: This phase Ib study aimed to establish the feasible everolimus dose given with standard-dose etoposide plus cisplatin (EP) for extensive-stage small-cell lung cancer (SCLC). PATIENTS AND METHODS: An adaptive Bayesian dose-escalation model and investigator opinion were used to identify feasible daily or weekly everolimus doses given with EP in adults with treatment-naive extensive-stage SCLC. A protocol amendment mandated prophylactic granulocyte colony-stimulating factor (G-CSF). Primary end point was cycle 1 dose-limiting toxicity (DLT) rate. Secondary end points included safety, relative EP dose intensity, pharmacokinetics, and tumor response. RESULTS:Patients received everolimus 2.5 or 5 mg/day without G-CSF (n=10; cohort A), 20 or 30 mg/week without G-CSF (n=18; cohort B), or 2.5 or 5 mg/day with G-CSF (n=12; cohort C); all received EP. Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively. Cycle 1 DLTs were neutropenia (cohorts A and B), febrile neutropenia (all cohorts), and thrombocytopenia (cohorts A and C). The most common grade 3/4 adverse events were hematologic. Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively). CONCLUSIONS:Everolimus 2.5 mg/day plus G-CSF was the only feasible dose given with standard-dose EP in untreated extensive-stage SCLC.
Entities:
Keywords:
cisplatin; etoposide; everolimus; phase I; small-cell lung cancer
Authors: Mariacarmela Santarpia; Maria Grazia Daffinà; Niki Karachaliou; Maria González-Cao; Chiara Lazzari; Giuseppe Altavilla; Rafael Rosell Journal: Transl Lung Cancer Res Date: 2016-02
Authors: Milind D Chalishazar; Sarah J Wait; Fang Huang; Abbie S Ireland; Anandaroop Mukhopadhyay; Younjee Lee; Sophia S Schuman; Matthew R Guthrie; Kristofer C Berrett; Jeffery M Vahrenkamp; Zeping Hu; Marek Kudla; Katarzyna Modzelewska; Guoying Wang; Nicholas T Ingolia; Jason Gertz; David H Lum; Sabina C Cosulich; John S Bomalaski; Ralph J DeBerardinis; Trudy G Oliver Journal: Clin Cancer Res Date: 2019-06-04 Impact factor: 12.531
Authors: Jeffrey A Kern; Jihye Kim; Daniel G Foster; Rangnath Mishra; Eric E Gardner; John T Poirier; Christopher Rivard; Hui Yu; James H Finigan; Afshin Dowlati; Charles M Rudin; Aik-Choon Tan Journal: J Thorac Oncol Date: 2020-06-26 Impact factor: 15.609
Authors: Wassim Abida; Matthew I Milowsky; Irina Ostrovnaya; Scott R Gerst; Jonathan E Rosenberg; Martin H Voss; Andrea B Apolo; Ashley M Regazzi; Asia S McCoy; Mariel E Boyd; Dean F Bajorin Journal: Bladder Cancer Date: 2016-01-07